A detailed history of Bank Of Montreal transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 13,259 shares of ARWR stock, worth $260,274. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,259
Previous 43,699 69.66%
Holding current value
$260,274
Previous $1.14 Million 77.44%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$19.36 - $29.54 $589,318 - $899,197
-30,440 Reduced 69.66%
13,259 $256,000
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $675,039 - $871,655
30,866 Added 240.52%
43,699 $1.14 Million
Q1 2024

May 13, 2024

BUY
$27.21 - $39.48 $25,795 - $37,427
948 Added 7.98%
12,833 $367,000
Q4 2023

Feb 08, 2024

BUY
$21.2 - $31.03 $30,570 - $44,745
1,442 Added 13.81%
11,885 $363,000
Q3 2023

Nov 01, 2023

SELL
$26.2 - $36.08 $7,309 - $10,066
-279 Reduced 2.6%
10,443 $280,000
Q2 2023

Aug 02, 2023

SELL
$25.16 - $41.38 $128,039 - $210,582
-5,089 Reduced 32.19%
10,722 $382,000
Q1 2023

Jun 13, 2024

BUY
$23.68 - $38.51 $142,435 - $231,637
6,015 Added 46.87%
18,848 $478,000
Q4 2022

Feb 01, 2023

BUY
$28.0 - $40.56 $79,016 - $114,460
2,822 Added 21.73%
15,811 $641,000
Q3 2022

Nov 10, 2022

BUY
$29.63 - $48.31 $58,726 - $95,750
1,982 Added 18.01%
12,989 $536,000
Q2 2022

Aug 11, 2022

BUY
$27.79 - $50.61 $47,715 - $86,897
1,717 Added 18.48%
11,007 $372,000
Q1 2022

May 12, 2022

SELL
$39.62 - $69.97 $82,568 - $145,817
-2,084 Reduced 18.32%
9,290 $423,000
Q4 2021

Feb 11, 2022

BUY
$58.09 - $82.51 $54,546 - $77,476
939 Added 9.0%
11,374 $780,000
Q3 2021

Nov 12, 2021

SELL
$58.38 - $84.96 $27,613 - $40,186
-473 Reduced 4.34%
10,435 $643,000
Q2 2021

Aug 12, 2021

BUY
$62.15 - $90.32 $677,932 - $985,210
10,908 New
10,908 $903,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.